Legacy App users can now access the Health Portal – just reset your password using email as username.

Why a 48% Ejection Fraction on TRT Deserves a Closer Look

Why a 48% Ejection Fraction on TRT Deserves a Closer Look

Viewing This Video Is A Member Exclusive Feature

But you don’t need membership to get Dr. O’Connor’s insight on this topic, it’s in the summary, key takeaways, and related drugs and conditions below.

Want to watch the full video? Join the Health Portal Today.

Join Now

Timeline

Timestamp
Topic
00:00
A viewer reports that a friend with heart failure and an ejection fraction of 48% was told by his TRT clinic that the result was fine. After acknowledging his international audience, Dr. O’Connor introduces the ABCDs™ framework and discusses blood pressure and steroid exposure as concerns requiring assessment.
02:00
Dr. O’Connor explains that ejection fraction measurements can vary with the imaging method and challenges dismissing the reported result. He then introduces heart failure with preserved ejection fraction to show why a higher percentage does not necessarily exclude heart failure.
03:50
The discussion turns to treatment, blood pressure control, and the heart’s ability to relax between beats. Dr. O’Connor connects steroid exposure and hypertension with changes in heart structure and emphasizes echocardiography and knowledgeable clinical assessment.
05:30
Dr. O’Connor encourages further evaluation and discusses blood pressure medicines, urine protein testing, and the connections among cardiovascular, kidney, and metabolic health. Jardiance and Farxiga enter the conversation as treatment options to discuss with healthcare providers, alongside concerns about access and cost.
07:33
The closing remarks describe the potential to stabilize or improve steroid-related heart dysfunction through medical care. Blood pressure management, SGLT2 inhibitors, and attention to excess weight are highlighted within that broader treatment discussion.

Video Summary

An ejection fraction of 48% should not be dismissed without understanding the rest of the cardiac assessment. Dr. Thomas O’Connor responds to a viewer whose friend reportedly has heart failure but was reassured by his TRT clinic that the result was fine.

The discussion explains why ejection fraction is important but does not tell the whole story. Dr. O’Connor notes that measurements can vary with the testing method and distinguishes impaired pumping function from heart failure with preserved ejection fraction, where a higher percentage does not exclude disease.

Blood pressure and previous steroid exposure are central concerns throughout the response. Dr. O’Connor discusses changes in heart muscle thickness and relaxation, emphasizing the value of echocardiography and assessment by a healthcare provider who understands these findings.

Treatment becomes the focus in the second half, including blood pressure management, angiotensin receptor blockers, and SGLT2 inhibitors such as Jardiance and Farxiga. Kidney function, urine protein, body weight, and metabolic health are brought into the same discussion rather than treating the heart as an isolated problem.

Dr. O’Connor closes by describing the potential for improvement in steroid-related heart dysfunction with appropriate care. His broader message is to seek a thorough evaluation, understand the findings, and discuss treatment options rather than accepting blanket reassurance from a clinic.

Drug Callouts

Drug
Description
Jardiance (Empagliflozin)
Jardiance is a brand name for empagliflozin, an SGLT2 inhibitor used in the treatment of type 2 diabetes, heart failure, and chronic kidney disease. Dr. O’Connor highlights it when discussing medicines that may help address heart failure and encourages viewers to raise treatment questions with their healthcare providers.
Farxiga (Dapagliflozin)
Farxiga is a brand name for dapagliflozin, an SGLT2 inhibitor used in the treatment of type 2 diabetes, heart failure, and chronic kidney disease. It appears alongside Jardiance in the closing explanation of medical approaches to improving heart failure outcomes after steroid exposure.

Condition Callouts

Condition
Description
Heart Failure
Heart failure is a clinical syndrome in which impaired heart function leads to inadequate circulation, elevated filling pressures, or both. The reported diagnosis and ejection fraction of 48% prompt Dr. O’Connor to challenge the clinic’s reassurance and call for a more complete assessment.
Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction is a form of heart failure in which the proportion of blood pumped out remains preserved despite abnormalities in cardiac function and filling pressures. Dr. O’Connor uses it to explain why ejection fraction alone cannot rule out heart failure.
Hypertension
Hypertension is persistently elevated blood pressure that places additional strain on the heart and blood vessels. Blood pressure control anchors the treatment discussion, particularly when considering heart muscle changes alongside testosterone or steroid exposure.
Diastolic Dysfunction
Diastolic dysfunction is impaired relaxation or filling of the heart between beats. The explanation of heart muscle stiffening connects this finding with the need to assess more than pumping percentage on an echocardiogram.

Key Takeaways

  • Ejection fraction is one part of a cardiac assessment, and the reported percentage needs to be interpreted alongside the testing method and other clinical findings.
  • A preserved ejection fraction does not exclude heart failure because abnormalities in relaxation and filling can still affect heart function.
  • Blood pressure deserves close attention when evaluating heart health after testosterone or steroid exposure.
  • Echocardiography can provide information about heart structure and function that a testosterone level or routine hormone panel cannot.
  • Heart, kidney, and metabolic health are connected, making urine protein, body weight, and glucose-related factors relevant to a broader assessment.
  • An abnormal heart assessment deserves an individualized treatment discussion rather than blanket reassurance from a TRT clinic.